论文部分内容阅读
项目组历经10年多时间,建立起符合国际GLP标准的非临床安全评价的关键技术平台,为加速我国创新药物走向国际市场提供技术支撑。全球创新药物的研发历史经验表明,有30%-40%的新药研发因安全性原因而导致失败。随着国内的新药研究投入和开发的蓬勃发展,我国急需建设符合国际GLP标准的非临床安全评价技术平台,以提升毒理学评价技术水平,降低新药研发的风险,使中国创制的新药走向
After more than 10 years, the project team has established a key technology platform for non-clinical safety evaluation in line with the international GLP standard and provided technical support for accelerating the innovation of Chinese medicines to the international market. The history of research and development of innovative drugs worldwide has shown that 30% -40% of new drug research and development failed due to safety reasons. With the vigorous development of new drug research and development in our country, we urgently need to build a non-clinical safety evaluation technology platform in line with the international GLP standard in order to enhance the technical level of toxicological evaluation and reduce the risk of new drug research and development,